(Alliance News) - Stock prices in London were red at midday on Monday, taking a tumble even as data showed continued recovery for the UK manufacturing sector. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Futura Medical PLC on Wednesday celebrated its "first set out meaningful revenues" in 2023, as sales for its erectile dysfunction treatment climbed. Read More
Futura Medical PLC - Guildford, England-based pharmaceutical company focused on sexual health products - Confirms that lead product Eroxon will from March 1 be available on prescription in England and Wales for the treatment of erectile dysfunction. Eroxon is a gel-based treatment designed to help the user obtain an erection, and serves as an alternative for people who are unwilling or unable to use medications like Viagra. Eroxon has also been available without a prescription in UK pharmacies since March last year. Read More
(Alliance News) - Stock prices in London pushed higher on Tuesday, with the FTSE 100 registering its first rise in four trading days, with oil major BP the star performer. Read More
(Alliance News) - Futura Medical PLC on Tuesday reported its first revenues in 2023, thanks to the successful global roll-out of Eroxon. Read More
(Alliance News) - Futura Medical PLC on Monday said that it has extended its exclusive licensing agreement with Cooper Consumer Health Group, a European self-care organisation, to January 2029. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Futura Medical PLC on Wednesday said the Mexican Secretariat of Health has granted over the counter sale marketing authorisation for its erectile dysfunction topical gel formulation Eroxon. Read More
Futura Medical PLC - Guildford, Surrey-based pharmaceutical company - Says that it has launched Exoron in the United Arab Emirates. Exoron, or MED3000, is a topical gel used to treat erectile dysfunction. It uses Futura's proprietary technology, DermaSys. The product is now available for purchase online through the BinSina Pharmacy in the UAE, the first market in the Middle East to stock the product. Read More
Futura Medical PLC - Guildford, Surrey-based pharmaceutical company - Receives European patent for erectile dysfunction treatment, MED3000, until 2040. Continues to pursue patent applications to provide wider patent protection. Chief Executive Officer James Barder says: "The allowance of this patent application further cements the intellectual property of MED3000, as we support our distributors' roll out of our fast acting topically applied gel for the treatment of erectile dysfunction available without a doctor's prescription across the world." Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Futura Medical PLC - Surrey, England-based pharmaceutical company - Says its distribution partner, Labatec Pharma, received regulatory approval for MED3000 in Saudi Arabia. MED3000 is Futura's topical, gel-based erectile dysfunction treatment. Labatec will exclusively launch and commercialise MED3000 under the brand name Eroxon, with initial launch planned in the final quarter of 2023. Adds the manufacturing of Eroxon for launch has been completed. Read More
(Alliance News) - Futura Medical PLC on Tuesday said it appointed Non-Executive Chair Jeff Needham as the successor to outgoing chair John Clarke, who has stepped down. Read More
(Alliance News) - Futura Medical PLC on Monday said it agreed a licensing deal with Haleon PLC for the rights to exclusively commercialise Futura's erectile dysfunction treatment Med3000 in the US. Read More
Futura Medical PLC - Guildford, Surrey-based pharmaceutical company - Says it is encouraged by the early growth trajectory of erectile dysfunction treatment gel Eroxon following its recent launch. "Both initial orders of Eroxon by our partners and in-market demand have been in line with our expectations and should continue to build as partners expand sales channels, numbers of outlets and new geographies," it adds. Predicts that net revenue for the six months ending June 30 will be no less than GBP1.5 million. Says momentum continues to build as it enters the commercialisation phase and positions itself to receive its first significant revenue in 2023. It previously in April said that its 2022 pretax loss widened to GBP6.9 million from GBP5.8 million the year before. Read More